GeneVentiv Therapeutics Announces Positive FDA INTERACT Feedback Supporting Advancement of GENV-HEM Gene Therapy for Hemophilia A with or without Inhibitors
GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting with the U.S. Food and Drug Administration (FDA) for the Company's lead program, GENV-HEM, a novel gene therapy for Hemophilia A with or without inhibitors (antibodies to Factor VIII). […]